Inactive Instrument

Company Galapagos NV Euronext Bruxelles

Stocks

GLPG

BE0003818359

Biotechnology & Medical Research

End-of-day quote Euronext Bruxelles
-	-

08-12	Tranche Update on Lakefront Biotherapeutics NV's Equity Buyback Plan announced on June 9, 2026.	CI
08-11	RBC Adjusts PT on Lakefront Biotherapeutics to $26 From $28, Keeps Sector Perform Rating	MT

Business description: Galapagos NV

Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.

Sales by Activity: Galapagos NV

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Research and Development (R&D)	485M	505M	240M	276M	1.11B

See all business segments

Geographical breakdown of sales: Galapagos NV

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
United States of America	468M	414M	240M	241M	1.08B
Europe	2.11M	3.55M	16K	34.86M	31.1M

See all geographic segments

Executive Committee: Galapagos NV

Manager	Title	Age	Since
Henry Gosebruch CEO	Chief Executive Officer	53	11/05/2025
Aaron Cox DFI	Director of Finance/CFO	41	06/07/2025
Christina Carlson COO	Chief Operating Officer	-	31/05/2026
Eric Hedrick CTO	Chief Tech/Sci/R&D Officer	61	07/06/2026
Sherri Spear IRC	Investor Relations Contact	-	-

See GALAPAGOS NV governance

Composition of the Board of Directors: Galapagos NV

Director	Title	Age	Since
Linda Higgins BRD	Director/Board Member	63	21/10/2019
Oleg Nodelman BRD	Director/Board Member	49	06/10/2024
Henry Gosebruch BRD	Director/Board Member	53	11/05/2025
Dawn Svoronos BRD	Director/Board Member	72	27/07/2025
Jane Griffiths BRD	Director/Board Member	71	27/07/2025
Neil Johnston BRD	Director/Board Member	59	31/10/2025
Devang Bhuva BRD	Director/Board Member	40	31/10/2025
Gino Santini CHM	Chairman	69	27/04/2026

Composition of the Board of Directors

Shareholders: Galapagos NV

Name	Stocks	%	Valuation
GILEAD SCIENCES, INC. 25.35 %	16,707,477	25.35 %	459 M
EcoR1 Capital, LLC 10.92 %	7,193,777	10.92 %	197 M
Van Herk Investments BV 7.035 %	4,635,672	7.035 %	127 M
Niche Asset Management Ltd. 0.1017 %	67,000	0.1017 %	2 M
Saint Olive Gestion SNC 0.0645 %	42,500	0.0645 %	1 M

Name	Stocks	%	Valuation
GILEAD SCIENCES, INC. 25.35 %	16,707,477	25.35 %	455 M
Tang Capital Management LLC 5.745 %	3,785,991	5.745 %	103 M
Madison Avenue Partners LP 5.472 %	3,606,203	5.472 %	98 M
Madison Avenue Partners LP 5.232 %	3,447,807	5.232 %	94 M
Prosight Management LP 3.101 %	2,043,344	3.101 %	56 M

List of GALAPAGOS NV shareholders

Company details: Galapagos NV

Galapagos NV

Industriepark Mechelen Noord

2800, Mechelen

+32 1 534 29 00

http://www.galapagos.com

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+2.37%	+2.30%	+3.39%	+22.74%	48.63B
REVOLUTION MEDICINES, INC.	-0.62%	+4.58%	+487.47%	+624.71%	46.3B
BEONE MEDICINES AG	+2.09%	+4.96%	+20.59%	+95.21%	41.97B
IQVIA HOLDINGS INC.	+3.85%	+3.13%	+29.60%	+16.50%	39.51B
CELLTRION, INC.	-0.72%	-7.79%	+17.87%	+47.98%	31.75B
MEDPACE HOLDINGS, INC.	+3.04%	+1.89%	+31.62%	+143.62%	16.48B
ASCENDIS PHARMA A/S	+4.33%	+1.63%	-	-	16.34B
EUROFINS SCIENTIFIC SE	+1.44%	+1.52%	+4.22%	+31.00%	14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+3.87%	+1.98%	+82.99%	+45.80%	13.33B
Average	+2.18%	+1.05%	+84.72%	+128.44%	29.81B
Weighted average by Cap.	+1.85%	+0.96%	+107.24%	+157.21%